Page 1393 - Williams Hematology ( PDFDrive )

1368 Part X: Malignant Myeloid Diseases Chapter 87: Myelodysplastic Syndromes 1369

344. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myel- granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes
odysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. using a meta-analysis approach. Cancer 115(4):706–715, 2009.
Blood 111(2):574–582, 2008. 372. Pomeroy C, Oken MM, Rydell RE, Filice GA: Infection in the myelodysplastic syn-
345. Rigolin GM, Porta MD, Ciccone M, et al: In patients with myelodysplastic syndromes dromes. Am J Med 90(3):338–344, 1991.
response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically 373. Boogaerts MA, Nelissen V, Roelant C, Goossens W: Blood neutrophil function in pri-
normal CD34 cells. Br J Haematol 126(4):501–507, 2004. mary myelodysplastic syndromes. Br J Haematol 55(2):217–227, 1983.
346. Musto P, Matera R, Minervini MM, et al: Low serum levels of tumor necrosis factor and 374. Davey FR, Erber WN, Gatter KC, Mason DY: Abnormal neutrophils in acute myeloid
interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythro- leukemia and myelodysplastic syndrome. Hum Pathol 19(4):454–459, 1988.
poietin. Haematologica 79(3):265–268, 1994. 375. Engelfriet CP, k HW, Klein HG, et al: International forum: Granulocyte transfusions.
347. Wallvik J, Stenke L, Bernell P, et al: Serum erythropoietin (EPO) levels correlate with Vox Sang 79(1):59–66, 2000.
survival and independently predict response to EPO treatment in patients with myelo- 376. Steensma DP: Hematopoietic growth factors in myelodysplastic syndromes. Semin
dysplastic syndromes. Eur J Haematol 68(3):180–185, 2002. Oncol 38(5):635–647, 2011.
348. Auerbach M, Ballard H: Clinical use of intravenous iron: Administration, efficacy, and 377. Vadhan-Raj S, Keating M, LeMaistre A, et al: Effects of recombinant human granu-
safety. Hematology Am Soc Hematol Educ Program 2010:338–347, 2010. locyte-macrophage colony-stimulating factor in patients with myelodysplastic syn-
349. Rizzo JD, Brouwers M, Hurley P, et al: American Society of Hematology/American dromes. N Engl J Med 317(25):1545–1552, 1987.
Society of Clinical Oncology clinical practice guideline update on the use of epoetin 378. Chuncharunee S, Intragumtornchai T, Chaimongkol B, et al: Treatment of myelodys-
and darbepoetin in adult patients with cancer. Blood 116(20):4045–4059, 2010. plastic syndrome with low-dose human granulocyte colony-stimulating factor: A mul-
350. Rose EH, Abels RI, Nelson RA, et al: The use of r-HuEpo in the treatment of anaemia ticenter study. Int J Hematol 74(2):144–146, 2001.
related to myelodysplasia (MDS). Br J Haematol 89(4):831–837, 1995. 379. Sultana TA, Harada H, Ito K, et al: Expression and functional analysis of granulocyte
351. Negrin RS, Stein R, Vardiman J, et al: Treatment of the anemia of myelodysplastic syn- colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic
dromes using recombinant human granulocyte colony-stimulating factor in combina- syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 121(1):63–75,
tion with erythropoietin. Blood 82(3):737–743, 1993. 2003.
352. Bessho M, Jinnai I, Matsuda A, et al: Improvement of anemia by recombinant ery- 380. Nimubona S, Grulois I, Bernard M, et al: Complete remission in hypoplastic acute
thropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell myeloid leukemia induced by G-CSF without chemotherapy: Report on three cases.
Cloning 8(6):445–458, 1990. Leukemia 16(9):1871–1873, 2002.
353. Stebler C, Tichelli A, Dazzi H, et al: High-dose recombinant human erythropoietin for 381. O’Malley DP, Whalen M, Banks PM: Spontaneous splenic rupture with fatal out-
treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemo- come following G-CSF administration for myelodysplastic syndrome. Am J Hematol
globinuria: A pilot study. Exp Hematol 18(11):1204–1208, 1990. 73(4):294–295, 2003.
354. Bowen D, Culligan D, Jacobs A: The treatment of anaemia in the myelodysplastic syn- 382. Arshad M, Seiter K, Bilaniuk J, et al: Side effects related to cancer treatment: CASE 2.
dromes with recombinant human erythropoietin. Br J Haematol 77(3):419–423, 1991. Splenic rupture following pegfilgrastim. J Clin Oncol 23(33):8533–8534, 2005.
355. Hellstrom E, Birgegard G, Lockner D, et al: Treatment of myelodysplastic syndromes 383. Jakob A, Hirsch FW, Engelhardt M: Successful treatment of a patient with myelodys-
with recombinant human erythropoietin. Eur J Haematol 47(5):355–360, 1991. plastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim.
356. Schouten HC, Vellenga E, van Rhenen DJ, et al: Recombinant human erythropoietin in Ann Hematol 84(10):694–695, 2005.
patients with myelodysplastic syndromes. Leukemia 5(5):432–436, 1991. 384. Jadersten M, Montgomery SM, Dybedal I, et al: Long-term outcome of treatment of
357. Stein RS, Abels RI, Krantz SB: Pharmacologic doses of recombinant human erythropoi- anemia in MDS with erythropoietin and G-CSF. Blood 106(3):803–811, 2005.
etin in the treatment of myelodysplastic syndromes. Blood 78(7):1658–1663, 1991. 385. Verhoef G, Van den Berghe H, Boogaerts M: Cytogenetic effects on cells derived from
358. Goy A, Belanger C, Casadevall N, et al: High doses of intravenous recombinant ery- patients with myelodysplastic syndromes during treatment with hemopoietic growth
thropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol factors. Leukemia 6(8):766–769, 1992.
84(2):232–237, 1993. 386. Tohyama K, Ohmori S, Michishita M, et al: Effects of recombinant G-CSF and GM-CSF
359. A randomized double-blind placebo-controlled study with subcutaneous recombinant on in vitro differentiation of the blast cells of RAEB and RAEB-T. Eur J Haematol
human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian 42(4):348–353, 1989.
Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 387. Ferrero D, Bruno B, Pregno P, et al: Combined differentiating therapy for myelodysplas-
103(4):1070–1074, 1998. tic syndromes: A phase II study. Leuk Res 20(10):867–876, 1996.
360. Thompson JA, Gilliland DG, Prchal JT, et al: Effect of recombinant human erythro- 388. Hofmann WK, Koeffler HP: Differentiation therapy for myelodysplastic syndrome.
poietin combined with granulocyte/macrophage colony-stimulating factor in the treat- Clin Cancer Res 8(4):939–941, 2002.
ment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 389. Kurzrock R, Cortes J, Thomas DA, et al: Pilot study of low-dose interleukin-11 in
95(4):1175–1179, 2000. patients with bone marrow failure. J Clin Oncol 19(21):4165–4172, 2001.
361. Spiriti MA, Latagliata R, Niscola P, et al: Impact of a new dosing regimen of epoetin alfa 390. Tsimberidou AM, Giles FJ, Khouri I, et al: Low-dose interleukin-11 in patients with
on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann bone marrow failure: Update of the M. D. Anderson Cancer Center experience. Ann
Hematol 84(3):167–176, 2005. Oncol 16(1):139–145, 2005.
362. Stone RM, Bernstein SH, Demetri G, et al: Therapy with recombinant human erythro- 391. Kuter DJ, Begley CG: Recombinant human thrombopoietin: Basic biology and evalua-
poietin in patients with myelodysplastic syndromes. Leuk Res 18(10):769–776, 1994. tion of clinical studies. Blood 100(10):3457–3469, 2002.
363. Gabrilove J, Paquette R, Lyons RM, et al: Phase 2, single-arm trial to evaluate the effec- 392. Greenberg PL, Garcia-Manero G, Moore M, et al: A randomized controlled trial of
tiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome
syndromes. Br J Haematol 142(3):379–393, 2008. receiving decitabine. Leuk Lymphoma 54(2):321–328, 2013.
364. Stasi R, Abruzzese E, Lanzetta G, et al: Darbepoetin alfa for the treatment of anemic 393. Kantarjian H, Fenaux P, Sekeres MA, et al: Safety and efficacy of romiplostim in patients
patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol
16(12):1921–1927, 2005. 28(3):437–444, 2010.
365. Moyo V, Lefebvre P, Duh MS, et al: Erythropoiesis-stimulating agents in the treat- 394. Kantarjian HM, Giles FJ, Greenberg PL, et al: Phase 2 study of romiplostim in patients
ment of anemia in myelodysplastic syndromes: A meta-analysis. Ann Hematol 87(7): with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
527–536, 2008. Blood 116(17):3163–3170, 2010.
366. Terpos E, Mougiou A, Kouraklis A, et al: Prolonged administration of erythropoietin 395. Sekeres MA, Kantarjian H, Fenaux P, et al: Subcutaneous or intravenous administra-
increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 tion of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syn-
patients. Br J Haematol 118(1):174–180, 2002. dromes. Cancer 117(5):992–1000, 2011.
367. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulat- 396. Wroblewski S, Shi W, Mudd P Jr, Aivado M: Eltrombopag in thrombocytopenic
ing agents and mortality in patients with cancer: A meta-analysis of randomised trials. patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid
Lancet 373(9674):1532–1542, 2009. leukemia after MDS: A phase I/II study. J Clin Oncol. 28:15s [abstract], 2010 (available
368. Jadersten M, Malcovati L, Dybedal I, et al: Erythropoietin and granulocyte-colony at http://meetinglibrary.asco.org/content/53792-74).
stimulating factor treatment associated with improved survival in myelodysplastic syn- 397. Mavroudi I, Pyrovolaki K, Pavlaki K, et al: Effect of the nonpeptide thrombopoietin
drome. J Clin Oncol 26(21):3607–3613, 2008. receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelo-
369. Cortelezzi A, Colombo G, Pellegrini C, et al: Bone marrow glycophorin-positive ery- dysplastic syndrome. Leuk Res 2011;35(3):323–328, 2010.
throid cells of myelodysplastic patients responding to high-dose rHuEPO therapy 398. Svensson T, Chowdhury O, Garelius H, et al: A pilot phase I dose finding safety
have a different gene expression pattern from those of nonresponders. Am J Hematol study of the thrombopoietin-receptor agonist, eltrombopag, in patients with mye-
83(7):531–539, 2008. lodysplastic syndrome treated with azacitidine. Eur J Haematol 93(5):439–445,
370. Negrin RS, Stein R, Doherty K, et al: Maintenance treatment of the anemia of myelo- 2014.
dysplastic syndromes with recombinant human granulocyte colony-stimulating factor 399. Tamari R, Schinke C, Bhagat T, et al: Eltrombopag can overcome the anti-megakary-
and erythropoietin: Evidence for in vivo synergy. Blood 87(10):4076–4081, 1996. opoietic effects of lenalidomide without increasing proliferation of the malignant
371. Mundle S, Lefebvre P, Vekeman F, et al: An assessment of erythroid response myelodysplastic syndrome/acute myelogenous leukemia clone. Leuk Lymphoma
to epoetin alpha as a single agent versus in combination with granulocyte- or 55(12):2901–2906, 2014.

Kaushansky_chapter 87_p1341-1372.indd 1368 9/21/15 11:06 AM